Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 12/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593659 | 0.80 | EDNRB (0.46) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL29370636 | 0.80 | EDNRB (0.46) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL31174746 | 0.78 | RXRA (0.45) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL25211129 | 0.78 | RXRA (0.45) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL29072666 | 0.78 | CTSK (0.33) | CYP11B1ACACBLRRK2 | |
| SCHEMBL26099703 | 0.77 | ACACB (0.37) | CYP11B1ACACBLRRK2 | |
| SCHEMBL25596642 | 0.77 | EDNRB (0.47) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL10805820 | 0.75 | RXRA (0.38) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL24589997 | 0.74 | RXRA (0.45) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL23978001 | 0.72 | UHRF1 (0.39) | CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-2021219594-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | EDNRB 304/4885EDNRA 387/4885KMT2A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.